Rankings / Cognitive

Cerebrolysin

Cognitive · Neurotrophic peptide mix

Tier C

Reviewed by Read Off Label · Last reviewed · How we grade

peptidebdnfindustry-funding-flagprescription
4.8 / 10
Tier C
Ev 4.5 Bn 5 Sf 5

Bottom line

Read Off Label grades Cerebrolysin as C (4.8/10) based on moderate-disputed evidence, med benefit magnitude, and a low-med-risk safety profile.

Manufactured by EVER Neuro Pharma in Unterach Austria via enzymatic proteolysis of porcine brain proteins — composition is a defined mixture of low-MW peptides and free amino acids but not fully reductionist ("defined biologic" vs single-compound contrast matters for QC).

Studied, labeled, or reported-use context: 10-30 mL IV or 5-10 mL IM daily for 10-21 day courses; multiple courses per year in chronic indications — Rx (Austria/Germany/EU/Russia/China/Korea/many Asian markets); NOT approved in US — FDA never reviewed; not individualized guidance.

What the evidence says

Manufactured by EVER Neuro Pharma in Unterach Austria via enzymatic proteolysis of porcine brain proteins — composition is a defined mixture of low-MW peptides and free amino acids but not fully reductionist ("defined biologic" vs single-compound contrast matters for QC). **Industry-funding caveat is central**: Cochrane reviews across three decades have consistently flagged that EVER Pharma sponsored or supplied study materials, randomization codes, and statisticians for most pivotal trials. **2023 Cochrane stroke review** (Ziganshina) concluded current RCT data do NOT support routine use AND found a 2.4-fold increase in non-fatal serious AEs across pooled trials — newest and most clinically important development since the entry was first written. **2019 Cochrane vascular dementia review** (Cui): modest cognitive benefit on MMSE and ADAS-cog+ across 6 RCTs n=597; no new RCTs eligible since — the field has stagnated. **CAPTAIN I-II TBI meta-analysis** (Poon 2021): small-to-medium effect at Day 30 and 90 in n=185 moderate-severe TBI; encouraging but small and manufacturer-sponsored. **2025 Patel MA** (Cureus August 2025) in n=2884 across 14 stroke RCTs reports positive early-recovery effect but does NOT escape the industry-funding overlap with Cochrane's source data. Evidence summary: decades of EU and Asian clinical use coexist with extensive industry funding; the multi-component biologic is difficult to characterize outside manufacturer-supplied product; and the 2023 Cochrane review reported a non-fatal serious-adverse-event signal. Clinical studies used manufacturer-supplied product; gray-market "Cerebrolysin" in research-chemical channels is compositionally uncharacterized.

Mechanism

Porcine brain-derived preparation of low-molecular-weight peptides and free amino acids produced by standardized enzymatic proteolysis (EVER Neuro Pharma; Unterach Austria); mimics endogenous neurotrophic factors with BDNF-like activity; multi-component biologic — defined mixture but not fully characterized vs single-compound drugs; used widely in EU/Russia/China/Korea/Asia for stroke; vascular dementia; and TBI

Studied, labeled, or reported dose & route

10-30 mL IV or 5-10 mL IM daily for 10-21 day courses; multiple courses per year in chronic indications

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Cerebrolysin's effects?
Read Off Label rates the evidence for Cerebrolysin as Moderate-Disputed and the benefit magnitude as med, producing an overall grade of C (4.8/10). Manufactured by EVER Neuro Pharma in Unterach Austria via enzymatic proteolysis of porcine brain proteins — composition is a defined mixture of low-MW peptides and free amino acids but not fully reductionist ("defined biologic" vs single-compound contrast matters for QC).
What safety findings are reported for Cerebrolysin?
Cerebrolysin has a low-med risk profile in the database. Low-Med (injection site reactions; rare hypersensitivity); newer safety signal: 2023 Cochrane reported ~2.4-fold increase in non-fatal serious adverse events across pooled stroke trials Legal status: Rx (Austria/Germany/EU/Russia/China/Korea/many Asian markets); NOT approved in US — FDA never reviewed.
What doses or routes are reported for Cerebrolysin?
10-30 mL IV or 5-10 mL IM daily for 10-21 day courses; multiple courses per year in chronic indications This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Cerebrolysin work?
Porcine brain-derived preparation of low-molecular-weight peptides and free amino acids produced by standardized enzymatic proteolysis (EVER Neuro Pharma; Unterach Austria); mimics endogenous neurotrophic factors with BDNF-like activity; multi-component biologic — defined mixture but not fully characterized vs single-compound drugs; used widely in EU/Russia/China/Korea/Asia for stroke; vascular dementia; and TBI

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.